Folprecht G - Search Results

1

Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer.

Jones RP, Hamann S, Malik HZ, Fenwick SW, Poston GJ, Folprecht G. Jones RP, et al. Among authors: folprecht g. Eur J Cancer. 2014 Jun;50(9):1590-601. doi: 10.1016/j.ejca.2014.02.024. Epub 2014 Mar 21. Eur J Cancer. 2014. PMID: 24661798 Review.

2

The role of new agents in the treatment of colorectal cancer.

Folprecht G, Köhne CH. Folprecht G, et al. Oncology. 2004;66(1):1-17. doi: 10.1159/000076329. Oncology. 2004. PMID: 15031593 Review.

3

[New therapy options in colorectal carcinoma].

Folprecht G, Köhne CH. Folprecht G, et al. Ther Umsch. 2004 Jun;61(6):373-8. doi: 10.1024/0040-5930.61.6.373. Ther Umsch. 2004. PMID: 15253162 Review. German.

4

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.

Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Köhne CH. Folprecht G, et al. Ann Oncol. 2004 Sep;15(9):1330-8. doi: 10.1093/annonc/mdh344. Ann Oncol. 2004. PMID: 15319237 Free article.

5

Current perspectives in the treatment of metastatic colorectal cancer.

Köhne CH, Folprecht G. Köhne CH, et al. Among authors: folprecht g. Ann Oncol. 2004;15 Suppl 4:iv43-53. doi: 10.1093/annonc/mdh904. Ann Oncol. 2004. PMID: 15477334 Free article. Review. No abstract available.

6

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.

Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Folprecht G, et al. Ann Oncol. 2005 Aug;16(8):1311-9. doi: 10.1093/annonc/mdi246. Epub 2005 May 3. Ann Oncol. 2005. PMID: 15870084 Free article.

7

Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.

Folprecht G, Köhne CH. Folprecht G, et al. Nat Clin Pract Oncol. 2005 Nov;2(11):578-87. doi: 10.1038/ncponc0353. Nat Clin Pract Oncol. 2005. PMID: 16270098 Review.

8

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.

Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH. Folprecht G, et al. Ann Oncol. 2006 Mar;17(3):450-6. doi: 10.1093/annonc/mdj084. Epub 2005 Nov 22. Ann Oncol. 2006. PMID: 16303861 Free article. Clinical Trial.

9

Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.

Folprecht G, Köhne CH, Lutz MP. Folprecht G, et al. Cancer Treat Res. 2007;134:425-40. doi: 10.1007/978-0-387-48993-3_28. Cancer Treat Res. 2007. PMID: 17633071 Review. No abstract available.

10

Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.

Folprecht G, Tabernero J, Köhne CH, Zacharchuk C, Paz-Ares L, Rojo F, Quinn S, Casado E, Salazar R, Abbas R, Lejeune C, Marimón I, Andreu J, Ubbelohde U, Cortes-Funes H, Baselga J. Folprecht G, et al. Clin Cancer Res. 2008 Jan 1;14(1):215-23. doi: 10.1158/1078-0432.CCR-07-1053. Clin Cancer Res. 2008. PMID: 18172273 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters